We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Moves -0.4%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Boston Scientific (BSX - Free Report) ending at $89.32, denoting a -0.4% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.43% for the day. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq lost 0.9%.
The medical device manufacturer's shares have seen a decrease of 0.83% over the last month, surpassing the Medical sector's loss of 7.03% and the S&P 500's loss of 1.98%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. The company's earnings per share (EPS) are projected to be $0.65, reflecting a 18.18% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $4.4 billion, reflecting a 18.15% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.46 per share and a revenue of $16.59 billion, indicating changes of +20% and +16.48%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Boston Scientific is carrying a Zacks Rank of #2 (Buy).
Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 36.46. This denotes a premium relative to the industry's average Forward P/E of 24.48.
We can additionally observe that BSX currently boasts a PEG ratio of 2.64. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BSX's industry had an average PEG ratio of 2.28 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 133, placing it within the bottom 48% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Stock Moves -0.4%: What You Should Know
The latest trading session saw Boston Scientific (BSX - Free Report) ending at $89.32, denoting a -0.4% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.43% for the day. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq lost 0.9%.
The medical device manufacturer's shares have seen a decrease of 0.83% over the last month, surpassing the Medical sector's loss of 7.03% and the S&P 500's loss of 1.98%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. The company's earnings per share (EPS) are projected to be $0.65, reflecting a 18.18% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $4.4 billion, reflecting a 18.15% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.46 per share and a revenue of $16.59 billion, indicating changes of +20% and +16.48%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Boston Scientific is carrying a Zacks Rank of #2 (Buy).
Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 36.46. This denotes a premium relative to the industry's average Forward P/E of 24.48.
We can additionally observe that BSX currently boasts a PEG ratio of 2.64. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BSX's industry had an average PEG ratio of 2.28 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 133, placing it within the bottom 48% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.